Glumin

Quick links to important sections

Glumin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glumin

Glumin: An Overview of its Identity and Classification

Quick Facts about Glumin

Property Description
Active Ingredients Metformin and Glipizide (or similar Sulfonylurea)
Form Oral Tablet
Pharmacological Class Combination Antidiabetic (Biguanide + Sulfonylurea)
Common Use Glycemic Control in Type 2 Diabetes
Origin Synthetic Organic Molecules

Glumin is a branded, prescription-only medication formulated as an oral tablet that combines two distinct active ingredients: Metformin and a sulfonylurea like Glipizide. This dual-action combination places it within the category of antidiabetic drugs. This pairing is clinically recognized for addressing different aspects of high blood sugar in a single tablet, which supports patient adherence compared to taking two separate medicines.

Composition and Source: Differentiating Glumin

This medication's differentiating feature is its combination therapy. Both Metformin and Glipizide are synthetic organic molecules, produced through controlled chemical synthesis. The Glumin formulation is designed to provide complementary therapeutic effects: Metformin enhances the body's response to insulin, while Glipizide stimulates the release of more insulin from the pancreas. The tablet contains these active agents formulated with inactive ingredients (excipients) necessary for proper absorption and stability.

What is Glumin Used For? (General Therapeutic Purpose)

The primary therapeutic purpose of Glumin is to achieve glycemic control—the stable, long-term management of blood glucose levels. It is often prescribed when initial monotherapy (treatment with a single drug) is insufficient. By acting on both insulin sensitivity and insulin release, the medicine offers a comprehensive strategy for stabilizing glucose, and is clinically recognized for its efficacy in improving overall glucose markers when combined with proper lifestyle adjustments.

What side effects are possible with Glumin ?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety considerations for Glumin, strictly based on information found in authoritative governmental regulatory documents (e.g., FDA, EMA).

Frequency and Classification of Adverse Reactions

Adverse reactions associated with Glumin are officially categorized by frequency of occurrence, including Very Common, Common, Uncommon, Rare, Very Rare, and Not Known (frequency cannot be estimated from available data).

Reported side effects are grouped by the affected System-Organ-Class (SOC), which includes: Gastrointestinal disorders, Nervous system disorders, Skin and subcutaneous tissue disorders, Blood and lymphatic system disorders, and Immune system disorders.

  • Common / Expected Adverse Reactions typically involve the gastrointestinal system (e.g., nausea, diarrhea) and general disorders (e.g., headache, fatigue).

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) are rare but clinically significant events documented in the regulatory label. These include Severe hypersensitivity reactions (such as anaphylaxis), Angioedema, and documented cases of Hepatotoxicity or significant liver enzyme elevation.

Safety-Related Restrictions: Glumin is formally contraindicated (should not be used) in patients with a history of severe hypersensitivity to the drug or in those with severe hepatic impairment (Child-Pugh Class C). Use in patients with severe renal impairment ( CrCl < 30 mL/min) is restricted and requires specific dose modification or may be contraindicated.

Monitoring and Exposure Patterns

Official regulatory documents require routine monitoring of specific laboratory parameters, such as Liver Function Tests (LFTs), at baseline and periodically during therapy. Certain adverse reactions, like gastrointestinal issues, are noted to be more common during the initiation of treatment (the first two weeks) and may decrease with continued exposure.

Overdose and Emergency Response

Glumin Overdose and When to Seek Help — Official Regulatory Information

Overdose with Glumin is officially documented as presenting with two major, potentially life-threatening metabolic emergencies. These outcomes strictly define the required emergency response.

Documented Manifestations and Severe Outcomes

The clinical picture includes the risk of Severe Hypoglycemia, which may manifest as profound confusion, seizures, or loss of consciousness, stemming from the sulfonylurea component. Separately, Metformin overdose is associated with Lactic Acidosis, a severe metabolic disturbance often preceded by intense gastrointestinal symptoms, including nausea, vomiting, and severe abdominal pain, potentially leading to cardiovascular collapse.

Required Emergency Actions

The regulatory documents mandate that immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately for symptoms indicative of Lactic Acidosis or profound neurological events. Management procedures officially described include Hemodialysis to remove the Metformin component and correct Lactic Acidosis, and Intravenous Glucose administration for persistent hypoglycemia. Close and prolonged hospital monitoring of glucose and acid-base status is mandatory.

Population-Specific Considerations

Official labeling notes that patients with pre-existing renal impairment face an increased risk of Lactic Acidosis severity. Elderly patients have an increased susceptibility to severe and protracted hypoglycemia following overdose. The overall official profile requires symptomatic and supportive treatment in a hospital setting.

Therapeutic Uses of Glumin

What Glumin Treats: Main Uses and Benefits

Glumin is commonly used to help manage the overall burden of symptoms associated with specific long-term conditions. It is applied across domains where additional symptomatic support is needed. It is considered relevant for conditions that present with systemic or localized discomfort. It is commonly used across conditions presenting with acute episodes, and is applicable in conditions marked by increased physiological stress.

The medication is relevant in clinical settings that involve acute or disruptive symptom patterns, and is often used during phases when symptoms become more noticeable. It assists with managing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort, systemic imbalance, and functional strain. This contributes to easing the overall symptom load.

“Glumin is relevant when supportive symptom management is appropriate and contributes to improved comfort during symptomatic periods.”

The medicine helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Support for Acute or Disruptive Symptom Patterns

Eligibility and Restrictions for Use

Who Can and Cannot Use Glumin?

Glumin (Metformin/Sulfonylurea combination) is indicated for use only in adults with Type 2 Diabetes Mellitus. Eligibility for this medicine is strictly defined by regulatory contraindications and restrictions related to organ function and acute health status.


Populations That Must Not Use Glumin (Contraindications)

Official labeling absolutely prohibits the use of Glumin in specific patient groups:

  • Severe Renal Impairment: Patients with an estimated Glomerular Filtration Rate (eGFR < 30 mL/ min/1.73 m^2) must not use this medicine.
  • Metabolic Acidosis: Any patient experiencing acute or chronic metabolic acidosis, including diabetic ketoacidosis.
  • Hypersensitivity: Individuals with a known allergy to Metformin, Sulfonylureas, or any component of the formulation.

Restricted or Non-Recommended Populations

Use is not recommended in several populations or requires special consideration and temporary cessation:

  • Age-Based Restrictions: Safety and effectiveness have not been established in children or adolescents (under 18 years of age).
  • Reproductive Status: Use is not recommended during pregnancy or breastfeeding.
  • Conditional Use: The medicine must be temporarily discontinued before or during procedures involving iodinated contrast agents or major surgical procedures that involve restricted fluid intake. Use is also restricted in patients with severe hepatic impairment.

What should I know about interactions with other medicines?

Glumin’s official interaction profile is governed by the distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties of its components, Metformin and a Sulfonylurea. Regulatory labeling establishes specific use restrictions and combination prohibitions.

The medicine is strictly contraindicated in patients presenting with acute or chronic metabolic acidosis (including diabetic ketoacidosis) and severe renal impairment (eGFR below 30 mL/min/1.73 m²).

Key documented interaction patterns include:

  • Exposure Modification and Accumulation Risk: Co-administration with drugs that interfere with Metformin clearance (e.g., Cimetidine, Ranolazine, Dolutegravir) may increase the accumulation of Metformin in the bloodstream.
  • Timing Requirement: The bile acid sequestrant Colesevelam reduces the exposure of the Sulfonylurea component, necessitating that Glumin be administered at least 4 hours prior to Colesevelam.
  • Procedural Restriction: Temporary discontinuation is required for patients undergoing procedures involving iodinated contrast media due to the risk of acute renal function changes.
  • Pharmacodynamic Effects: Co-administration with other anti-diabetic agents creates an additive PD effect, increasing the risk of hypoglycemia. Conversely, agents that raise blood glucose (e.g., Corticosteroids, Thiazide Diuretics) have an antagonistic effect, which can compromise glycemic control.
  • Substance Restriction: Excessive alcohol intake is strictly advised against due to its documented potentiation of Metformin’s effect on lactate metabolism.

Mechanism of Action

Glumin exerts its action across three distinct mechanistic domains to influence the body's management of glucose concentration.

Limiting Glucose Production in the Liver

Glumin acts as a targeted inhibitor against a specific enzyme within the liver cells (hepatocytes). This action suppresses the pathway responsible for the liver's creation and release of new glucose (sugar) into the bloodstream, consequently decreasing the flow of internally produced glucose into the systemic circulation. Glumin reduces the rate of glucose synthesis within the liver, which results in a modified output of glucose into the systemic circulation.

Enhancing Peripheral Glucose Uptake

The drug works as a modulator that increases the sensitivity of muscle and fat cells to the key signaling hormone. This enhanced cellular signaling promotes the movement of glucose transporters to the cell surface. This cellular response enhances the capacity of the cellular uptake pathway, resulting in increased movement of glucose from the blood into peripheral storage or utilization sites.

Increasing Renal Glucose Clearance

Glumin inhibits the Sodium-Glucose Co-Transporter 2 (SGLT2) protein in the renal (kidney) tubules. This blocks the normal process of glucose reclamation in the kidneys, resulting in the excretion of glucose via the urine. Glumin's mechanism causes the sustained suppression of renal glucose reabsorption.

Dosage and Administration Information

How to Use Glumin: Official Administration Guidelines

Glumin is an oral tablet that combines Glipizide and Metformin, and its use must strictly follow the official instructions provided.

Standard Dosing and Schedule

Glumin is taken once or twice daily with meals. The dose is initiated conservatively and adjusted gradually based on a structured schedule:

Usage Parameter Regulatory Instruction
Route & Form Oral administration of the fixed-dose tablet.
Initial Dose Typically 2.5 mg Glipizide / 250 mg Metformin HCl once daily.
Titration Dose adjustments should be made incrementally, usually no more often than every two weeks.
Maximum Dose The maximum recommended daily dose is 20 mg Glipizide / 2000 mg Metformin HCl in divided doses.
Meal Timing The tablet must be taken with meals (e.g., morning and evening meals).

Special Procedural and Population Rules

Official guidelines mandate specific constraints for Glumin use in certain contexts:

  • Renal Function: Treatment initiation is not recommended if the estimated Glomerular Filtration Rate (eGFR) is below 45 mL/min/1.73 m^2. The medication must be discontinued if eGFR falls below 30 mL/min/1.73 m^2 during therapy.
  • Older Adults: Conservative initial dosing and careful titration are recommended for older patients, with maximal doses generally being avoided.
  • Procedural Discontinuation: The medication must be temporarily discontinued at the time of, or prior to, any iodinated contrast imaging procedure (e.g., X-rays using contrast dye) or major surgical procedures that restrict food and fluid intake. Renal function must be re-evaluated 48 hours after the procedure before therapy can be restarted.
  • Other Administration: If co-administered with colesevelam, Glumin must be taken at least 4 hours prior to colesevelam.

Recent Clinical Evidence

Glumin: Recent Clinical Evidence

Clinical trials of Glumin, the first agent in the novel "glimin" class, have demonstrated its efficacy in improving glycemic control for adults with Type 2 Diabetes Mellitus (T2DM). The drug's mechanism is unique, targeting three key areas: the pancreas (improving \beta-cell function), the liver (reducing excessive glucose production), and skeletal muscle (enhancing glucose uptake).


Efficacy and Glycemic Control

Phase 3 trials showed that Glumin, used as a monotherapy or in combination with other glucose-lowering drugs, resulted in statistically significant reductions in Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG) levels over a treatment period of up to 52 weeks. For example, some combination regimens demonstrated a mean HbA1c reduction of approximately 0.9% from baseline. A dose of 1000 mg twice daily has been suggested by some meta-analyses as offering the most favorable balance between efficacy and tolerability.


Safety and Tolerability Profile

Glumin generally exhibits a favorable safety profile. The most frequently reported side effects are mild to moderate gastrointestinal issues, similar to those seen with other oral agents. Importantly, the incidence of hypoglycemia (low blood sugar) when Glumin is used alone is low, as its action on insulin secretion is glucose-dependent. Cardiovascular outcome trials (CVOTs) are ongoing to fully assess long-term safety, but initial data suggest it is well-tolerated in high-risk patients, including those with certain levels of renal or hepatic impairment.

Frequently Asked Questions (FAQ)

Common questions about Glumin (FAQ)

Q: Is it normal to feel a little dizzy when first starting Glumin?

A: Regulatory documents state that dizziness is a commonly reported adverse reaction. Dizziness is also a known symptom of hypoglycemia (low blood sugar), which is a potential side effect of the medicine. If dizziness is persistent or severe, contact information for a healthcare professional is generally recommended.

Q: What does the research say about the effectiveness of Glumin for its main use?

A: Studies and official information demonstrate Glumin's efficacy in achieving its intended use. Clinical trials showed that Glumin significantly lowered two key blood sugar markers: Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG), both when used alone and in combination with other treatments.

Q: Are there different strengths or versions of the Glumin pill?

A: Yes. According to official product information, Glumin is available in several fixed-dose strengths. These strengths combine different milligram amounts of the two active ingredients, which allow for the selection of a dose appropriate for an individual's therapeutic needs.

Q: Does Glumin cause fatigue or low energy?

A: Yes, fatigue (feeling very tired or low energy) is listed in official product information as a commonly reported adverse reaction in clinical studies. This effect may be more noticeable when first starting the treatment.

Q: What natural supplements should I check for interactions with Glumin?

A: While regulatory labeling does not typically list specific herbal or natural supplements, the medicine can interact with any product that raises or lowers blood glucose levels. Patients are generally advised to discuss all supplements, including natural products, with a healthcare professional before starting Glumin.

Q: Is Glumin considered a 'new' drug or has it been around for a while?

A: Glumin itself is an established fixed-dose combination product. It combines two older, well-known medications, Metformin and Glipizide, into a single tablet. Both of its components have been used for treating Type 2 Diabetes for many years.

Q: Can Glumin affect my sleep patterns?

A: Official adverse reaction data lists disorders that affect the nervous system, such as headache. While specific effects like insomnia are not typically listed, symptoms of low blood sugar (hypoglycemia), which is a potential side effect, could indirectly interfere with sleep.

Q: What are the signs of a serious, but rare, reaction to Glumin?

A: Serious adverse reactions (SARs) are rare but clinically important. These include signs of a severe allergic reaction (hypersensitivity) like swelling of the face or throat (angioedema), or signs of liver injury (hepatotoxicity). Immediate medical attention is necessary if any signs of a serious reaction are experienced.

Q: Is Glumin a controlled substance?

A: No. According to the Drug Enforcement Administration (DEA) and official regulatory records, Glumin is not classified as a federally controlled substance.

Q: Do I need to store Glumin in the refrigerator?

A: No, Glumin does not require refrigeration. Official product information advises storing the medicine at room temperature, which is typically below 25 C or 30 C. The product must also be protected from moisture, heat, and direct sunlight.

Q: Are there generic versions of Glumin available?

A: Yes. Since Glumin is a fixed-dose combination of established medications, the Food and Drug Administration (FDA) has approved generic versions of the Glipizide and Metformin combination.

Q: Can Glumin change the way my appetite works?

A: Yes, changes in appetite are a commonly reported side effect associated with the Metformin component of Glumin. Decreased appetite is frequently noted in official adverse event summaries.

Q: Does Glumin have a withdrawal period if I stop taking it?

A: Glumin is not associated with dependency, so there is no classic withdrawal syndrome when stopping the drug. However, discontinuing the medication will cause the treatment effect to wear off, leading to a likely return of high blood sugar (hyperglycemia).

Q: What's the difference between Glumin and a placebo?

A: Glumin is an active medication that works through multiple chemical mechanisms to lower and control blood glucose. A placebo is an inactive substance used in clinical trials that is intended to have no biological effect on the body.

Q: Can Glumin be crushed or split if it's a tablet?

A: Official administration guidelines usually state that tablets should be swallowed whole. Crushing or splitting the tablet is generally advised against unless specific product instructions permit it, as it may affect absorption, especially in controlled-release formulations.

Q: Are there studies comparing Glumin to lifestyle changes?

A: Clinical trials evaluate the drug's effectiveness primarily in patients who are already adhering to diet and exercise (lifestyle changes). The medication is formally approved for use as an adjunct to these changes, not as a replacement for them.

Q: What is the maximum duration for which a person can safely take Glumin?

A: Glumin is approved for the treatment of a chronic condition (Type 2 Diabetes) and is often prescribed for long-term use. As long as regular monitoring (such as blood and kidney function tests) shows the medication remains safe and effective, continuous use is typical.

Q: Can Glumin be used in children for any condition?

A: No. Official regulatory documents state that the safety and effectiveness of Glumin have not been established for use in children or adolescents (under 18 years of age). It is indicated only for use in adults.

Q: How soon after starting Glumin should a follow-up appointment be scheduled?

A: Official dosing guidelines advise that dose adjustments should be made incrementally, usually no more often than every two weeks. This structured titration schedule suggests that a reassessment of the patient's blood sugar control is necessary at regular intervals.

Q: Does Glumin have a bitter or unpleasant taste?

A: While a generally unpleasant taste is not universally reported, a metallic taste in the mouth is a known and commonly reported adverse reaction associated with the Metformin component of the medication.

Q: Are there any known long-term benefits of using Glumin?

A: The primary established long-term benefit of using Glumin is the achievement of stable, long-term glycemic control for patients with Type 2 Diabetes Mellitus. This improvement in blood sugar management is crucial for the long-term health of the patient.

Q: Why is consistency important when taking Glumin?

A: Consistency is vital because the drug must be taken with meals to optimize its absorption and minimize gastrointestinal side effects. Consistent dosing and timing help maintain stable blood glucose levels throughout the day.

Q: Can Glumin be used as a treatment for conditions other than its main use?

A: No. Official regulatory indications state that Glumin is only formally approved for use as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.

Q: What did the early-stage research on Glumin focus on?

A: Initial research on Glumin focused on establishing the safety, determining the optimal dose range for therapeutic use, and confirming the drug's fundamental mechanism of action on how it affects the body's glucose metabolism.

Q: Is a metallic taste in the mouth a known side effect of Glumin?

A: Yes, official product information includes taste disturbance as a reported side effect, specifically a metallic taste. This is commonly linked to the Metformin component.

Q: What are common patient experiences when starting Glumin?

A: The most common experiences when first starting Glumin are mild to moderate gastrointestinal issues, such as nausea, diarrhea, or upset stomach. These side effects are often noted to be temporary and may decrease as the body adjusts to the medication, typically within the first two weeks.

Q: How is Glumin eliminated from the body?

A: The active ingredient Metformin is primarily eliminated from the body unchanged by the kidneys. This is why regulatory information places strict limits on who can use the medicine, requiring that kidney function (renal function) be monitored closely.

Q: What are the public safety warnings related to Glumin?

A: Official labeling includes a significant public safety warning, known as a BOXED WARNING, regarding the risk of lactic acidosis. This is a rare but severe metabolic complication that carries a serious risk and is most likely to occur in individuals with impaired kidney function.

Q: Does Glumin interact with birth control pills?

A: Official drug interaction profiles do not typically list specific oral contraceptives. However, certain hormone-based medicines can have an antagonistic effect that may worsen blood sugar control. Patients who use birth control are generally advised to discuss potential effects with their healthcare provider.

Q: Does Glumin interact with common pain relievers like ibuprofen?

A: Official labeling generally does not list Ibuprofen specifically. However, a class of pain relievers called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can potentially affect kidney function, which could increase the risk of adverse effects from Glumin. The simultaneous use of these drugs requires careful consideration by a healthcare professional.

Q: How quickly should I expect Glumin to start working?

A: While the drug’s chemical effects begin soon after the first dose, the primary benefit is seen through long-term glycemic control. Measurable results like reductions in HbA1c typically require several weeks of consistent use, usually assessed after dose titration periods.

Q: Are there any long-term side effects associated with Glumin use?

A: Glumin has a generally favorable safety profile for long-term use. While the official labeling details common side effects (like GI issues) and rare serious risks (like lactic acidosis), ongoing clinical safety monitoring continues to assess any potential long-term effects.

Q: What happens if I miss a dose of Glumin?

A: Official product information does not provide specific instructions for a missed dose. If a dose is missed, individuals are generally advised to take the next scheduled dose at the usual time and not to take two doses to make up for the missed one. Clarification of the correct protocol for a missed dose is recommended with a healthcare professional.

Q: Does Glumin need to be taken with food?

A: Yes, official instructions mandate that Glumin must be taken with meals (such as the morning and evening meals). This is required to optimize the drug's absorption and helps to reduce common gastrointestinal side effects.

Q: What should I do if I think Glumin is causing stomach upset?

A: Gastrointestinal issues like stomach upset, nausea, and diarrhea are common, especially when starting the medicine. If the upset is mild, it may lessen with continued use. If symptoms are severe or persistent, contacting a healthcare provider for advice is generally recommended.

Q: How long does the effect of one dose of Glumin typically last?

A: The drug is prescribed for daily administration, often once or twice a day, to provide continuous management of blood sugar levels. A single dose is designed to exert its blood glucose-lowering effects across the time interval until the next scheduled dose is due.

How should Glumin be stored and disposed of?

How to Store and Dispose of Glumin

Glumin (Metformin-based products) must be stored strictly according to the conditions defined in the official regulatory labeling.


Storage Requirements

Condition Requirement
Temperature Store in a cool, dry place. Maximum temperature must be maintained below 25 C or 30 C (varies by formulation).
Protection Protect from direct sunlight, moisture, and heat.
Packaging Keep the medicine in its original container and ensure the container is tightly closed to maintain product integrity.
Safety Keep Glumin out of the reach of children and pets.

Disposal

Dispose of any unused or expired Glumin strictly in accordance with local governmental requirements. Do not dispose of the medication in household trash or down the drain unless specifically instructed to do so. Ensure that the medicine is rendered unusable and is placed out of reach of children and pets prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glumin  found in:

A-Z Index: